Assessment of 111In-Ibritumomab pretreatment imaging in 90Y-Ibritumomab radioimmunotherapy for relapsed or refractory low-grade B cell lymphoma.

被引：0
|
作者：
Kaneko, K. [1 ]
Uike, N. [1 ]
Shinozaki, K. [1 ]
Choi, I. [1 ]
机构：
[1] Kyushu Natl Canc Ctr, Fukuoka, Japan
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2013年 / 40卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S372 / S372
页数：1
相关论文
共 50 条
  • [41] B-Cell non-Hodgkin lymphoma:: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy-initial experience
    Ulaner, Gary A.
    Colletti, Patrick M.
    Conti, Peter S.
    RADIOLOGY, 2008, 246 (03) : 895 - 902
  • [42] Rituximab and yttrium-90 ibritumomab tiuxetan radioimmunotherapy may be feasible options in patients with low-grade lymphoma of the orbit
    Esmaeli, B
    Pro, B
    Saville, MW
    McLaughlin, P
    BLOOD, 2005, 106 (11) : 278B - 278B
  • [43] Radioimmunotherapy with 90Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network
    Hohloch, K.
    Zinzani, P. L.
    Linkesch, W.
    Jurczak, W.
    Deptala, A.
    Lorsbach, M.
    Windemuth-Kiesselbach, C.
    Wulf, G. G.
    Truemper, L. H.
    BONE MARROW TRANSPLANTATION, 2011, 46 (06) : 901 - 903
  • [44] Efficacy and safety of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin®) therapy with rituximab maintenance in patients with untreated low-grade follicular lymphoma.
    Sweetenham, JW
    Dicke, K
    Arcaroli, J
    Kogel, K
    Rana, TM
    Rice, LL
    BLOOD, 2004, 104 (11) : 720A - 720A
  • [45] Therapy with 90Y Ibritumomab tiuxetan in Relapsed/Refractory Non-Hodgkin Lymphoma. Analysis of recent outcomes.
    Baringo, T.
    Lievano, P.
    Navarro, P.
    Arroyo, E.
    Ananos, M.
    De la Cueva, L.
    Gonzalez, M.
    Abos, M.
    Giraldo, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S419 - S419
  • [46] 90Y-Zevalin® (90Y-Ibritumomab tiuxetan) radioimmunotherapy (RIT) consolidation in mantle cell lymphoma (MCL) patients, not illegible for intensive therapy protocols
    Jurczak, Wojciech
    Giza, Agnieszka
    Zimowska-Curylo, Dagmara
    Hubalewska-Dydejczyk, Alicja
    Sowa-Staszczak, Anna
    Knopinska-Posluszny, Wanda
    Hellmann, Andrzej
    Zdziarska, Barbara
    Wrobel, Tomasz
    Krycz-Krzemien, Slawomira
    Poplawska, Lidia
    Walewski, Jan
    Skotnicki, Aleksander B.
    BLOOD, 2007, 110 (11) : 196B - 196B
  • [47] Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab
    A J Davies
    Oncogene, 2007, 26 : 3614 - 3628
  • [48] Radioimmunotherapy for B-cell lymphoma:: Y90 ibritumomab tiuxetan and I131 tositumomab
    Davies, A. J.
    ONCOGENE, 2007, 26 (25) : 3614 - 3628
  • [49] Comparison of 131I-Tositumomab (Bexxar®) and 90Y-Ibritumomab (Zevalin®) therapy of refractory/relapsed non-Hodgkin lymphoma
    Iagaru, A.
    Zhu, H.
    Mari, C.
    Knox, S. J.
    Ganjoo, K.
    Goris, M. L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 : S168 - S168
  • [50] Radioimmunotherapy with 90Y-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network
    K Hohloch
    P L Zinzani
    W Linkesch
    W Jurczak
    A Deptala
    M Lorsbach
    C Windemuth-Kiesselbach
    G G Wulf
    L H Truemper
    Bone Marrow Transplantation, 2011, 46 : 901 - 903
12345